Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 125

Results For "ISA"

1276 News Found

Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets
News | July 01, 2021

Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets

TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg


Dr. Reddy's announces commercial launch of 2DG
News | June 29, 2021

Dr. Reddy's announces commercial launch of 2DG

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's


Shilpa Medicare receives DRDO approval for 2DG manufacturing
News | June 26, 2021

Shilpa Medicare receives DRDO approval for 2DG manufacturing

2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country


Vaishali Pharma bags $100,000 order from Russia
News | June 23, 2021

Vaishali Pharma bags $100,000 order from Russia

The company has predominantly built a portfolio into veterinary products


Shilpa Medicare launches dissolving oral thin films of Paracetamol
News | June 23, 2021

Shilpa Medicare launches dissolving oral thin films of Paracetamol

Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world


Zydus and Bayer announce extension of their JV
News | June 21, 2021

Zydus and Bayer announce extension of their JV

Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline


India aims to vaccinate 1 crore people every day
News | June 12, 2021

India aims to vaccinate 1 crore people every day

India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021


Bayer acquires Noria and PSMA Therapeutics
News | June 07, 2021

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)


Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers